Behavioral Effects of Pregabalin and Cannabis

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Cannabis-use Disorders

In brief

Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use disorders. The purpose of the present study is to evaluate the ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a medication for cannabis-use disorders.

Key facts

Study ID

NCT01511640

Run by

Joshua A. Lile, Ph.D.

People needed

30

Starts

2017-02-01

Expected to finish

2020-03-15

Last updated by the study team

2021-09-10

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• regular cannabis use
• good health other than cannabis use
• willingness to attempt abstinence
• effective form of birth control in female subjects
• available for up to 6 hrs every day for two 2-week test periods with an intervening break of 7-10 days each
• located in close proximity to University of Kentucky

You may not qualify if…

• medical screening outcomes outside normal ranges or deemed clinically insignificant
• medical history that would contraindicate pregabalin administration

Where it is running

• Laboratory of Human Behavioral Pharmacology — Lexington, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.